Improvement in quality of life for cancer patients treated with epoetin alfa

被引：7
|
作者：
Libretto, SE
Barrett-Lee, PJ
Gorst, DW
Kaczmarski, R
McAdam, K
Stevenson, P
Thomas, R
机构：
[1] Janssen Cilag Ltd, High Wycombe HP14 4HJ, Bucks, England
[2] Velindre Hosp, Clin Trials Unit, Cardiff, S Glam, Wales
[3] Christie Hosp, Adult Leukaemia Unit, Manchester, Lancs, England
[4] Royal Lancaster Infirm, Dept Haematol, Lancaster, England
[5] Hillingdon Hosp, Dept Haematol Med, Uxbridge, Middx, England
[6] Peterborough Dist Gen Hosp, Peterborough, Cambs, England
[7] Newcastle Gen Hosp, Ctr Canc, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England
[8] Bedford Hosp, Primrose Unit, Bedford, Beds, England
来源：
EUROPEAN JOURNAL OF CANCER CARE | 2001年 / 10卷 / 03期
关键词：
human erythropoietin; epoetin alfa; quality of life;
D O I：
10.1046/j.1365-2354.2001.00264.x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anaemia is a common complication of cancer and cancer therapies, and fatigue is one of the most common symptoms of anaemia, disrupting functional performance and reducing overall quality of life. The positive effects of treating renal patients with recombinant human erythropoietin are well documented. This case report series details the specific effects of fatigue on individual patients with cancer and their way of life, and describes their significant improvement in lifestyle following the reversal of anaemia using recombinant human erythropoietin, epoetin alfa.
引用
收藏
页码：183 / 191
页数：9
相关论文
共 50 条
12345